[NKT cell-mediated immunotherapy for hematological malignancies].
Fujii
Shin-ichiro
S
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001549:Benzamides; D003131:Combined Modality Therapy; D019337:Hematologic Neoplasms / Q000276:immunology* / Q000628:therapy*; D006801:Humans; D000068877:Imatinib Mesylate; D007113:Immunity, Innate; D007167:Immunotherapy / Q000379:methods* / Q000639:trends; D007694:Killer Cells, Natural / Q000276:immunology*; D008213:Lymphocyte Activation; D010879:Piperazines / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D016176:T-Lymphocyte Subsets / Q000276:immunology*
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate